# FDA 483 - Unilever Manufacturing (US), Inc. - March 10, 2020

Source: https://www.keypedia.com/records/483/unilever-manufacturing-us-inc/ea9a9dcc-f342-4bfa-a8b8-37e7301b3a01

> FDA 483 for Unilever Manufacturing (US), Inc. on March 10, 2020. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Unilever Manufacturing (US), Inc.
- Inspection Date: 2020-03-10
- Product Type: drugs
- Office Name: Dallas District Office
- Summary: An FDA inspection of Unilever Manufacturing (US), Inc. in Jonesboro, AR, revealed significant deficiencies in their quality system. Observations included a failure to adequately document conclusions and follow-up for investigations into out-of-specification batches and corrective and preventive actions (CAPAs). Additionally, the firm's quality control unit did not consistently follow its own procedures for deviation investigation and management, resulting in numerous open and unmonitored deviation reports.

## Related Documents

- [483 - 2025-09-15](https://www.keypedia.com/records/483/unilever-manufacturing-us-inc/6484c3b4-13a5-4381-8634-48dfc2fcef3e)

## Related Officers

- [Investigator](https://www.keypedia.com/people/shatina-r-alridge/f4715fcf-fb27-4ef3-8289-adfff2db62bf)

Company: https://www.keypedia.com/companies/unilever-manufacturing-us-inc/ae587d51-1cf8-4ced-af22-8da0d2758cf6

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9